Patients with metastatic colorectal cancer must have their tumor tested for mutations in the RAS genes (KRAS and NRAS, specifically exons 2, 3, and 4) before receiving anti-EGFR therapy. Tumors with mutations in these genes are constitutively activated downstream of EGFR and will not respond to EGFR blockade. Therefore, only patients with RAS wild-type tumors are candidates for cetuximab or panitumumab therapy.

Break down complex topics into smaller, manageable chunks for easier recall.

Zambia

• Naomi Miselo – 31 pts

• Visual Pathway Lesions
• Positive and Negative Symptoms
• Hallucinations and Delusions
• Antipsychotic Medications
• Emergency: Environmental Emergencies